Pertuzumab Injection - Physical Form: Liquid

3

100 Pack/Packs

5 Pack/Packs

1 Vial/Vials

Liquid

Liquid

Liquid

Dry place

Store at 2AdegC - 8AdegC

Dry And Cool Place

5000 Per Month

Minimum 50 Per Day

10 Per Week

Omalizumab

Olimab 60mg Injection contains Denosumab, a monoclonal antibody used to treat osteoporosis and other conditions associated with bone loss. It is commonly prescribed for postmenopausal women and men at high risk of fractures, helping to strengthen bones and reduce the likelihood of broken bones. Olimab 60mg Injection is also used to prevent bone-related complications in patients with certain cancers, including multiple myeloma and cancers that have spread to the bones. It works by blocking RANK ligand, a protein responsible for bone breakdown, thereby increasing bone density and improving bone strength. Adequate calcium and vitamin D supplementation is essential during treatment to support bone health and reduce the risk of low calcium levels. Patients with moderate kidney impairment may require close monitoring of renal function while receiving this medication. Olimab 60mg Injection should not be used by individuals with a known allergy to Denosumab or any of its ingredients and should be used cautiously in patients with pre-existing hypoparathyroidism. As its safety and effectiveness have not been established in children and adolescents, this medication is not recommended for individuals under 18 years of age. When used as prescribed, Olimab 60mg Injection can play an important role in managing osteoporosis and protecting against bone-related complications.